Britain begins review to speed access to new drugs
LONDON (Reuters) – The British government has launched a review to speed the path to market for new drugs and medical devices in an attempt to improve patient care and make the country a more attractive place for investment in life sciences. British manufacturing relies heavily on the pharmaceuticals sector, including domestic giants GlaxoSmithKline and AstraZeneca, but companies complain that the state-run National Health Service (NHS) is too slow to adopt new treatments. …
